The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: A report from the Italian Pediatric Group by Locatelli, Franco et al.
The outcome of children with Fanconi anemia given
hematopoietic stem cell transplantation and the influence of
fludarabine in the conditioning regimen: a report from the Italian
pediatric group 
Franco Locatelli, Marco Zecca, Andrea Pession, Giuseppe Morreale, Daniela Longoni,
Paolo Di Bartolomeo, Fulvio Porta, Franca Fagioli, Bruno Nobili, Maria Ester Bernardo,
Chiara Messina
From Oncoematologia Pediatrica,
Fondazione IRCCS Policlinico San
Matteo, Università di Pavia, Pavia, Italy
(FL, MZ, MEB); Clinica Pediatrica,
Università di Bologna, Ospedale
Sant’Orsola Malpighi, Bologna, Italy
(AP); Dipartimento di Ematologia e
Oncologia Pediatrica, Istituto Giannina
Gaslini, Genova, Italy (GM); Clinica
Pediatrica, Università di Milano-
Bicocca, Ospedale Nuovo San Gerardo,
Monza, Italy (DL); Divisione di
Ematologia, Ospedale di Pescara,
Pescara, Italy (PDB); Clinica Pediatrica,
Università di Brescia, Spedali Civili,
Brescia, Italy (FP); Clinica Pediatrica,
Ospedale Infantile Regina Margherita,
Torino, Italy (FF); Clinica Pediatrica, I°
Policlinico, IIa Università di Napoli,
Napoli, Italy  (BN); Clinica Pediatrica,
Università di Padova, Padova, Italy
(CM).
Acknowledgments: we wish to thank the
GITMO (Gruppo Italiano Trapianto
Midollo Osseo) for supporting this study
and IBMDR (Italian Bone Marrow Donor
Registry) for the donor searches and
identification.
Funding: this work was partly
supported by grants from the AIRC
(Associazione Italiana Ricerca sul
Cancro), CNR (Consiglio Nazionale
delle Ricerche), MURST (Ministero
dell’Università e della Ricerca
Scientifica e Tecnologica), European
Union (FP6 programs ALLOSTEM) and
Fondazione IRCCS (Istituto di Ricovero
e Cura a Carattere Scientifico)
Policlinico San Matteo to FL.
Manuscript received February 26,
2007.
Manuscript accepted July 20, 2007.
Correspondence:
Franco Locatelli, Oncoematologia
Pediatrica, Fondazione IRCCS Policlinico
San Matteo e Università di Pavia.
E-mail: f.locatelli@smatteo.pv.it
Background and Objectives
Hematopoietic stem cell transplantation (HSCT) still represents the only treatment
potentially able to prevent/rescue the development of marrow failure and myeloid
malignancies in patients with Fanconi anemia (FA). While in the past HSCT from an
HLA-identical sibling was proven to cure many patients, a higher incidence of treat-
ment failure has been reported in recipients of an unrelated donor (UD) or HLA-par-
tially matched related allograft.
Design and Methods
We analyzed the outcome of 64 FA patients (age range, 2-20 years) who underwent
HSCT between January 1989 and December 2005. Patients were transplanted from
either an HLA-identical sibling (n=31), an UD (n=26), or an HLA-partially matched rel-
ative (n=7). T-cell depletion of the graft was performed in patients transplanted from
an HLA-disparate relative.
Results
The 8-year estimate of overall survival (OS) for the whole cohort was 67%; it was 87%,
40% and 69% when the donor was an HLA-identical sibling, an UD and a mismatched
relative, respectively (p<0.01). The outcome of recipients of grafts from an UD
improved over time, the probability of survival being 10% and 72% for patients trans-
planted before and after 1998, respectively (p<0.05). The OS probability of children
who did or did not receive fludarabine in preparation for the allograft was 86% and
59%, respectively (p<0.05).
Interpretation and Conclusions
These data, useful for counselling, provide support to the concept that a relevant pro-
portion of FA patients undergoing HSCT can now be successfully cured, even in the
absence of an HLA-identical sibling, especially if the conditioning regimen includes flu-
darabine.
Key words: Fanconi anemia, unrelated donor, fludarabine, hematopoietic stem cell
transplantation. 
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Fanconi anemia (FA) is a rare, genetically heteroge-neous, inherited disorder clinically characterised bycongenital abnormalities, progressive bone marrow
failure and a predisposition to develop malignancies, espe-
cially acute myeloid leukemia (AML) and squamous cell
carcinoma (SCC).1-4 Hematopoietic stem cell transplanta-
tion (HSCT) still represents the only option able to defini-
tively cure the marrow failure associated with this disease,
as well as to prevent/treat myeloid malignancies, although
it does not prevent the occurrence of solid tumors, mostly
head and neck SCC.5-7 The use of conditioning regimens
based on reduced doses of cyclophosphamide, either alone
or together with limited field radiotherapy, has cured a
large proportion of patients transplanted from an HLA-
identical sibling.5,8,9 Results of unrelated donor (UD) HSCT
have been less encouraging, mainly due to increased diffi-
culties with engraftment and higher incidence of both
acute and chronic graft-versus-host disease (GVHD).10,11
Better results were recently reported in a retrospective
study including both pediatric and adult FA patients trans-
planted from an UD.12 A significant contribution to this
improved outcome was provided by the use of fludarabine
as part of the conditioning regimen,12 this finding confirm-
ing previous reports on HSCT from alternative donors
including either anecdotal cases or a limited number of
patients.13-16 We here report the outcome of 64 pediatric FA
patients transplanted in Italy from either an HLA-identical
sibling, an UD, or an HLA-partially matched relative. 
Design and Methods
Data concerning patient and disease characteristics, as
well as transplantation outcome, were collected by means
of a standardized questionnaire of the AIEOP
(Associazione Italiana di Ematologia e Oncologia
Pediatrica) Registry for each patient enrolled into this
study. This study includes patients with a diagnosis of FA,
confirmed by the presence of multiple chromosome
breaks, enhanced by incubation with cross-linking agents,
who received an allogeneic HSCT between January 1989
and December 2005. A total of 64 children with FA trans-
planted from an HLA-identical sibling (n=31), an unrelated
volunteer (n=26), or an HLA-partially matched relative
(n=7) were included in the analysis. Fifteen of these 64
patients, all transplanted from an HLA-identical sibling,
have been previously reported.17 UD were located through
a network of international bone marrow donor
Registries.18 In all donor-recipient pairs, histocompatibility
was determined by serology for HLA-A and -B antigens
and by DNA typing for HLA-DRB1 locus (conventional
typing). In all patients transplanted from an UD, HLA-
DRB1 typing was performed using a high-resolution allel-
ic technique. After January 1998, high-resolution molecu-
lar typing was also performed to characterize HLA class I
loci of both donors and patients in UD transplants. Bone
marrow was used as the source of stem cells in 52 patients,
whereas six patients were transplanted with cord blood
cells. All patients transplanted from an HLA-partially
matched relative but one, transplanted with bone marrow
cells, were given T-cell-depleted peripheral blood progeni-
tor cells. CD34+ cells were positively selected using the
CliniMacs one-step procedure (Miltenyi Biotech, Bergisch
Gladbach, Germany). After transplantation, the seven chil-
dren given a T-cell-depleted allograft received either
cyclosporine A (CsA) or tacrolimus for 40-60 days in order
to minimize the risk of graft rejection. Details on the
patients’ and donors’ characteristics, conditioning regimen,
GVHD prophylaxis, as well as on the median number of
bone marrow and cord blood nucleated cells infused, are
reported in Table 1. Preparative regimens varied, mainly
according to the patients’ age and transplant Center proto-
cols (Table 1). Twenty-five patients received a preparative
regimen including the combination of fludarabine (30
mg/m2/day for 4 consecutive days) and cyclophosphamide
(300 mg/m2/day for 4 consecutive days).19 Thirty children
received a conditioning regimen based on the use of
cyclophosphamide, either alone or in combination with
radiotherapy (mainly involving limited field of irradiation).
The remaining nine patients were transplanted after het-
erogeneous pre-transplantation regimens. As GVHD pro-
phylaxis, most of the HLA-identical sibling HSCT recipi-
ents received CsA alone, while children transplanted from
an UD were given CsA together with a short course of
methotrexate. Pre-transplant antithymocyte globulin was
used in all recipients of a T-cell depleted allograft, in 21 out
of the 26 patients transplanted from an unrelated volunteer
and in 12 children given HSCT from an HLA-compatible
sibling (see also Table 1 for further details). 
Definition of outcomes
The primary outcomes were: (i) transplantation-related
mortality (TRM), defined as all causes of death related to
the transplantation procedure; (ii) overall survival (OS),
which was measured as the time interval between the date
of transplantation and the date of death from any cause or
the date of last follow-up for survivors. Other outcomes
were: (iii) hematopoietic recovery: neutrophil and platelet
recoveries being analyzed separately, and defined, respec-
tively, by a neutrophil count greater than 0.5×109/L for 3
consecutive days and an unsupported platelet count
greater than 50×109/L for 7 consecutive days. Absence of
hematopoietic recovery at day 60, second transplantation
or autologous hematopoietic reconstitution were consid-
ered as failure of engraftment. iv) graft-versus-host disease:
acute and chronic GVHD were diagnosed and graded at
each transplant Center according to the Seattle criteria.20,21
Patients surviving for more than 14 and 100 days post-
transplantation were evaluated for acute and chronic
GVHD occurrence, respectively. 
Statistical analysis
Analysis used December 31, 2005 as the report date, i.e.,
the day at which all Centers locked data on patients’ out-
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comes. Patients were censored at the time of death or at
last follow-up.  Univariate and multivariate proportional
hazard regression models were used to identify independ-
ent patient-, donor- and transplantation-related variables
influencing the different outcomes by means of log-rank
tests and Cox proportional hazard models. Since
hematopoietic recovery and development of GVHD are
considered events which compete with death, estimations
of the incidence of these events relied on the non-paramet-
ric estimator of cumulative incidence curves, while predic-
tive analyses were based on the proportional hazards
model for the subdistribution of competing risks.22,23 All
results are expressed as 8-year probability or 8-year cumu-
lative incidence (%) with a 95% confidence interval (95%
CI). p values >0.1 are reported as non-significant (N.S.); p
values between 0.05 and 0.1 were also considered non-sig-
nificant, but are reported in detail; p values <0.05 were con-
sidered statistically significant and are reported in detail.
Results
Neutrophil and platelet engraftment, and graft rejection
Graft failure occurred in four patients at 20, 25, 29 and
30 days after HSCT; two had primary graft failure, while
two children experienced secondary loss of the graft after
transient engraftment of donor cells. All these four patients
(two given HSCT from an HLA-identical sibling, one from
a partially matched family donor and one from an UD)
were re-transplanted from the same donor, and one of the
patients, transplanted from an HLA-identical sibling and
who experienced secondary graft failure, reached sus-
tained engraftment of donor hematopoiesis after a third
allograft. This patient is currently alive with normal blood
counts and without any sign of GVHD. The cumulative
incidence of primary and secondary graft failure was 6%
(95% CI, 2-16%). For patients who engrafted, the median
time to neutrophil recovery was 13 days (range, 8-46),
whereas the median time to platelet recovery was 21 days
(range, 7-107). The only factor which negatively influenced
neutrophil and platelet engraftment in multivariate analy-
sis was the use of methotrexate for GVHD prophylaxis
(data not shown). 
Acute and chronic GVHD
Sixty-three out of the 64 patient enrolled in the study,
surviving more than 14 days after HSCT, were evaluated
for the occurrence of acute GVHD. Twenty-three of them
experienced grade II-IV acute GVHD; the cumulative prob-
ability of developing grade II-IV acute GVHD was 37%
(95% CI, 26-51%), whereas that of developing grade III-IV
acute GVHD was 13% (95% CI, 7-24%). Multivariate
analysis did not identify any variable predicting the occur-
rence of acute GVHD. Chronic GVHD developed in 13 out
of the 51 patients surviving more than 100 days after the
allograft and, thus, at risk of this complication. All patients
with chronic GVHD had previously had acute GVHD. Five
out of these 13 patients had extensive chronic GVHD and
eight had limited chronic GVHD. The overall cumulative
probability of developing chronic GVHD was 26% (95%
CI, 16-42%), while that of developing the extensive form
was 11% (CI 5-26%). Only the occurrence of grade II-IV
acute GVHD predicted the development of chronic GVHD
in multivariate analysis (71% vs. 3% for patients who did
or did not have acute GVHD, respectively, p<0.0001).
Transplantation-related mortality
Nineteen patients died of transplantation-related com-
plications at a median time of 88 days after the allograft
(range, 8 days–4.5 years). The 8-year cumulative incidence
of TRM was 33% (95% CI, 23-49%, see also Figure 1 for
further details). It was 14% (95%, CI 6-35) for patients
receiving HCST from an HLA-compatible sibling, 60%
(95% CI, 40-89) for patients transplanted from an UD and
29% (95% CI, 9-92) for those given transplantation from
an HLA disparate relative (p<0.01). Details on 6-month
Table 1. Patient, donor and transplantation characteristics of the
64 FA patients included in the study.
Number of patients 64 (100%)
Gender
Males 39 (61%)
Females 25 (39%)
Median age at diagnosis and range (years) 6 (1–13)
Median age at HSCT and range (years) 9 (2–20)
Median interval from diagnosis to HSCT (months) 20 (2–190)
Type of donor employed
Matched family donor 31 (48%)
Matched unrelated donor 26 (41%)
HLA-partially matched family donor 7 (11%)
Number of cells infused
Bone marrow recipients (nucleated cells×108/kg) 4.5 (0.9–13.7)
Cord blood recipients (nucleated cells×107/kg) 3.1 (2.5–9.1)
Peripheral blood recipients (CD34+ cells×106/kg ) 15.1 (9-30)
Conditioning regimen
CY-based
CY alone 6 (9%)
CY + irradiation ± other 22 (34%)
CY + thiotepa 2 (3%)
Fludarabine based
Fludarabine +CY 25 (40%)
Other regimens 9 (14%)
Serotherapy (ATG) 40 (62%)
GVHD prophylaxis 
CsA 17 (27%)
CsA + ATG 6 (14%)
CsA + MTX 6 (9%)
CsA + MTX + ATG 25 (39%)
CsA + Steroids 1 (2%)
CsA + Steroids + ATG 2 (3%)
T-cell-depletion 7 (6%)
Use of G-CSF after HSCT
Yes 42 (66%)
No 22 (34%)
HSCT: hematopoietic stem cell transplantation; CY: cyclophosphamide; ATG: anti-thymo-
cyte globulin; GVHD: graft-versus-host disease; CsA: cyclosporine A; MTX, methotrexate;
G-CSF: granulocyte colony-stimulating factor.
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TRM for patients transplanted from either a relative or an
UD according to the transplant period are reported in
Figure 2. In univariate analysis, also the following factors
were associated with increased risk of transplant-related
death: ≥20 months between diagnosis and transplantation
(p=0.05), a conditioning regimen not including fludarabine
(p=0.04), the administration of granulocyte colony-stimu-
lating factor (G-CSF) (p<0.01) and the occurrence of grade
II-IV acute GVHD (p<0.01) or of chronic GVHD (p=0.02).
However, in multivariate analysis only the occurrence of
grade II-IV acute GVHD (relative risk=3.7; p=0.028) and a
graft from an UD (relative risk=5.3; p=0.019) remained
associated with an increased TRM. 
One patient, transplanted from an HLA-compatible sib-
ling after a conditioning regimen including total body irra-
diation and cyclophosphamide and who had developed
both grade II acute GVHD, requiring prolonged steroid
treatment, and limited chronic GVHD, involving oral
mucosa, died 4.5 years after transplantation due to a
tongue carcinoma.
Figure 1. Eight-year Kaplan-Meier estimate of survival (SUR) and
event-free survival (EFS) as well as 8-year cumulative incidence of
transplant-related mortality (TRM) and graft rejection (REJ) for the
whole cohort of patients. In the calculation of EFS, both death and
graft failure were considered events.
Figure 2. Probability of 180-day transplant-related mortality for
patients transplanted from either an unrelated donor (A) or an HLA-
identical sibling (B) according to the year of transplantation.
Figure 3. Probability of survival for patients transplanted from either
an unrelated donor (A) or an HLA-identical sibling (B) according to
the year of transplantation.
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Overall survival
Forty-five patients are alive with sustained donor
engraftment, the median follow-up of surviving patients
being 6 years (range, 3 months–16 years). The 8-year
Kaplan-Meier estimate of OS is 67% (95% CI, 55-80, see
also Figure 1). In patients transplanted from an HLA-iden-
tical sibling, an UD and a mismatched relative, the OS
probability at 8 years is 87% (95% CI, 74-99%), 40%
(95% CI, 16-64) and 69% (95% CI, 32-100), respectively
(p=0.003) (see also Table 2). The outcome of patients trans-
planted from an unrelated donor improved  significantly
over time, the probability of OS being 10% (95% CI, 0-
29), and 72% (95% CI, 48-96) for children transplanted
before and after 1998, respectively (p= 0.005; see Figure
3A). By contrast, there was no significant difference in the
outcome of children transplanted from an HLA-identical
sibling before and after 1998 (Figure 3B). Patients who did
or did not receive fludarabine in the conditioning regimen
had a probability of OS at 8 years of 86% (95% CI, 71-
100%) and 59% (95% CI, 43-74%), respectively (p=0.04,
Figure 4). Children who did not receive G-CSF after HSCT
had a better OS than that of patients who received G-CSF,
the OS being 85% (95% CI, 70-100) and 59% (95% CI, 31-
76), respectively (p=0.02) (see also Table 2). The 8-year OS
was 43% (95% CI, 21-65%) and 85% (95% CI, 73-96%)
for children who did or did not experience grade II-IV
acute GVHD, respectively (p=0.003). The estimated prob-
ability of OS in patients without chronic GVHD was 92%
(95% CI, 83-100%), while it was 71% (95% CI, 38-100%)
for patients with limited chronic GVHD and 30% (95%
CI, 0-77) for patients with extensive disease (p=0.011) (see
also Table 2).
Table 2. Univariate analysis of overall survival.
Variable N. of patients Events Probability of overall survival at 8 years (95% CI) P
Gender
Male 39 12 68% (53-83) N.S.
Female 25 7 65% (42-88)
Age at diagnosis
<6 years 33 11 63% (46-81) N.S.
≥6 years 31 8 71% (54-89)
Year of transplantation
Before 1998 31 13 58% (41-75) 0.083
After 1998 33 6 76% (59-94)
Age at transplantation
<9 years 33 9 70% (53-87) N.S.
≥9 years 31 10 65% (47-83)
Interval diagnosis – HSCT
<20 months 32 6 79% (64-94)) 0.053
≥20 months 32 13 55% (36-74)
Donor
Matched family donor 31 4 87% (74-99) 0.003
Matched unrelated donor 26 13 40% (16-64)
Partially matched family donor 7 2 69% (32-100)
Stem cell source
Bone marrow 52 15 64% (55-82) N.S.
Peripheral blood 6 1 80% (45-100)
Cord blood 6 3 50% (10-90)
Cell dose (bone marrow only)
<4.5 x 108/Kg 21 8 61% (40-82) N.S.
≥4.5 x 108/Kg 24 6 67% (44-90)
Use of fludarabine
No 39 16 59% (43-74) 0.04
Yes 25 3 86% (71-100)
Use of G-CSF
No 22 1 85% (70-100) 0.02
Yes 42 18 59% (31-76)
Use of methotrexate
No 33 7 78% (63-92) 0.074
Yes 31 12 53% (31-75)
Use of serotherapy
No 24 6 75% (57-92) N.S.
Yes 40 13 62% (45-79)
Acute GVHD grade*
0 – I 40 6 85% (73-96) 0.003
II – IV 23 12 43% (21-65)
Chronic GVHD**
Absent 38 3 92% (83-100) 0.011
Limited 8 2 71% (38-100)
Extensive 5 3 30% (0-77)
*Only the 63 patients surviving at least 14 days after transplantation were evaluated for acute GVHD occurrence. **Only the 51 patients surviving at least 100 days after transplantation were evaluated for
chronic GVHD occurrence. HSCT: hematopoietic stem cell transplantation; GVHD: graft-versus-host disease; G-CSF: granulocyte colony-stimulating factor.
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In multivariate analysis, only two factors were associat-
ed with a better probability of OS: use of fludarabine in the
conditioning regimen and an HLA-identical sibling as the
donor (see also Table 3). All patients surviving with sus-
tained engraftment, except the two with extensive chron-
ic GVHD, have a Karnofsky/Lansky score of 100%.
Discussion
This retrospective, multicenter analysis evaluated the
outcome of 64 Italian pediatric patients with FA given
HSCT in the last 17 years. We found that the type of donor
significantly influenced the outcome, as recipients of allo-
graft from an HLA-identical sibling had a better probability
of survival in comparison to children transplanted from an
UD. The 87% probability of OS at 8 years after the allo-
graft observed in our 31 patients transplanted from an
HLA-identical sibling is comparable to that reported in
another, previously described cohort of Italian patients17
and only marginally improved over time, suggesting that it
will be difficult to further ameliorate the outcome of
patients transplanted from an HLA-identical sibling.
The 8-year Kaplan-Meier estimate of OS in our 26
patients transplanted from an UD was 40%, which is
comparable to that in the other few studies which ana-
lyzed the outcome of FA patients given HSCT from an
unrelated volunteer.5,10,12,24 Graft rejection, regimen-related
toxicity and high risk of GVHD have been reported to be
the greatest obstacles to successful outcome in patients
with FA given HSCT from an UD.5,10,12,24 Only one patient
of our cohort transplanted from an unrelated volunteer
experienced graft failure. GVHD and infectious compli-
cations were the main contributors to the deaths that
occurred in our patients transplanted from an UD. The
outcome of recipients of grafts from UD improved
remarkably over time. Several factors related to the opti-
mization of the preparative regimens and GVHD pro-
phylaxis may have contributed to the improved outcome
of our children transplanted in the last years. Moreover,
the possibility of selecting an UD using high-resolution
molecular typing for both class I and class II HLA-alleles
has been demonstrated to decrease the risk of GVHD
and TRM.25,26 Indeed, the probability of survival of our FA
patients transplanted from an UD after 1998, the year in
which high-resolution molecular typing for both HLA
class I and II antigens became available in most Centers,
was comparable to that of patients receiving transplanta-
tion in the same time period from an HLA-compatible
sibling. A patient’s age less than 10 years predicted a bet-
ter outcome in the experience on UD-HSCT recently
reported by the Center for International Blood and
Marrow Transplantation Research.12 We were unable to
confirm this finding, probably because most of our
patients were transplanted early, the median age at time
of allograft being only 9 years.
Although employed in a limited number of patients,
fludarabine-containing regimens were found to be asso-
ciated with better outcome than other regimens.
Fludarabine-based conditioning regimens, capable of
intense T-cell immunosuppression, have been reported
to lead to early, stable engraftment with minimal toxici-
ty in patients with several malignant and non-malignant
diseases unable to tolerate conventional myeloablative
therapy.27,28 FA patients are natural candidates for non-
myeloablative stem cell transplantation after a fludara-
Table 3. Multivariate analysis for overall survival.
Variable Relative risk (95% CI) P
of treatment failure
Interval diagnosis – transplantation
≥20 vs. <20 months 1.66 (0.60-4.60) N.S.
Year of transplantation
Before 1998 vs. after 1998 1.05 (0.22-4.97) N.S.
Donor
UD vs. MFD 7.65 (1.24-47.15) 0.0283
PMFD vs. MFD 2.16 (0.74-16.20) N.S.
Use of Fludarabine
Yes vs. no 0.16 (0.02-0.99) 0.0495
Use of MTX in GVHD prophylaxis
Yes vs. no 1.09 (0.26-4.59) N.S.
Use of G-CSF
Yes vs. no 4.74 (0.50-45.00) N.S.
Acute GVHD
Grade II-IV vs. grade 0-I 2.24 (0.61-8.18) N.S.
HSCT: hematopoietic stem cell transplantation; UD: unrelated donor; MFD: matched family
donor; PMFD: partially matched family donor; MTX: methotrexate; GVHD: graft-versus-host
disease; G-CSF: granulocyte colony-stimulating factor.
Figure 4. Influence of fludarabine in the conditioning regimen on
the probability of survival at 8 years for the whole cohort of
patients. Patients receiving fludarabine as preparation for the allo-
graft did significantly better than those who did not receive fludara-
bine.
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bine-containing regimen because of the hypersensitivity
of their cells to DNA cross-linking. The favorable role
played by fludarabine in FA patients has been described
in reports from single centers13–16 and, more recently, in a
large cohort of matched or one-antigen mismatched
unrelated bone marrow donor recipients.12 In this latter
study, the use of fludarabine improved neutrophil recov-
ery, decreased 100-day TRM, and improved 3-year
adjusted OS rate, which was 52% and 13% in patients
who did or did not receive fludarabine, respectively.  
Grade II-IV acute GVHD had a detrimental effect in uni-
variate analysis on the probability of OS in our patients and
there was also a negative trend for chronic GVHD.
Previous grade II-IV acute GVHD was the only factor pre-
dicting the occurrence of chronic GVHD in our cohort.
Patients with FA have been documented to be at high risk
of developing solid tumors, in particular SCC of the head
and neck.3,29-31 Chronic GVHD has also been known to ren-
der non-FA patients at higher risk of SCC of the oral
mucosa and the skin, when these areas are involved by
GVHD.29 The correlation between GVHD and subsequent
occurrence of secondary SCC in patients with FA, already
at risk of this complication, has been recently demonstrat-
ed.31 Consequently, as adequate in vivo depletion or modu-
lation of T cells can decrease the risk of GVHD significant-
ly, it may also decrease, in the long-term, the risk of SCC. 
Our FA patients given G-CSF after transplantation were
found to have a worse outcome in univariate analysis. A
previously published study on acute leukemia patients has
shown that the use of this cytokine after allografting is
associated with an increased risk of TRM, translating into
reduced survival and leukemia-free survival rates.32 Several
biological mechanisms can be hypothesized to explain the
detrimental effect played by G-CSF administered after
HSCT. Production of interleukin-12 was found to be pro-
foundly impaired in patients given either an unmanipulat-
ed or a T-cell-depleted graft and who received G-CSF after
the allograft.33,34 Several studies in human volunteers and
animals also showed that G-CSF increases monocyte pro-
duction of interleukin-10,35 which is known to inhibit both
the ability to produce interleukin-12 and the stimulatory
capacity of dendritic cells, and to promote Th2 immune
deviation.36 Since a high level of production of interleukin-
12 by dendritic cells is a key factor in the initiation of pro-
tective Th1 immunity against fungi, bacteria, and virus-
es,37,38 it is reasonable to hypothesize that G-CSF adminis-
tration after transplantation may, at least partly, contribute
to the post-graft immune deficiency syndrome and to the
risk of dying from transplantation-related complications.
Only two of the seven patients given a T-cell-depleted
allograft from an HLA-disparate relative died; the remain-
ing patients benefited from sustained engraftment of donor
hematopoiesis which led to normalization of blood counts,
without any evidence of GVHD. This result suggests that
transplantation of megadoses of T-cell-depleted CD34+
cells may be considered in patients lacking a suitable relat-
ed or unrelated HLA-compatible donor, especially if
patients are transplanted in an experienced center able to
offer adoptive immunotherapy for the prevention/treat-
ment of infectious complications.16,39 It is reasonable to
speculate that high doses of normal hematopoietic progen-
itors, having a growth advantage in comparison to progen-
itors of FA patients, contributed significantly to the favor-
able outcome of our patients.
In conclusion, the results of the present study indicate
that the outcome of FA patients given HSCT from an UD
have become comparable in recent years to that of patients
transplanted from an HLA-identical sibling. Moreover, they
suggest that there is an advantage from using fludarabine in
the preparation for the allograft. Although obtained in a
limited number of patients, the results of patients given a
T-cell-depleted HSCT from an HLA-partially matched rela-
tive are also encouraging and deserve further investigation.
Appendix
The following AIEOP-HSCT centers and investigators reporting
data on the patients included in this analysis (the number of
patients transplanted in each single Center is given in brackets):
Oncoematologia Pediatrica, Fondazione IRCCS Policlinico San
Matteo, Università di Pavia, Franco Locatelli, Marco Zecca,
Giovanna Giorgiani, Maria Ester Bernardo (28 patients)
Dipartimento di Ematologia e Oncologia, Ospedale Giannina
Gaslini, Genova, Giorgio Dini, Edoardo Lanino, Giuseppe
Morreale, Carlo Dufour (9 patients) Divisione di Ematologia,
Ospedale di Pescara, Paolo Di Bartolomeo (6 patients) Clinica
Pediatrica, Università di Milano-Bicocca, Ospedale Nuovo San
Gerardo, Monza, Cornelio Uderzo, Adriana Balduzzi, Daniela
Longoni, Giuseppe Masera (5 patients) Clinica Pediatrica,
Spedali Civili, Università di Brescia, Fulvio Porta, Alessandro
Plebani (4 patients) Clinica Pediatrica Università di Padova,
Chiara Messina, Simone Cesaro, Modesto Carli (4 patients)
Clinica Pediatrica, Ospedale Regina Margherita, Università di
Torino, Franca Fagioli, Enrico Madon (3 patients) Clinica
Pediatrica, Università di Cagliari, Franca Argiolu, Renzo
Galanello (2 patients) Oncoematologia Pediatrica, Ospedale
Santa Chiara, Pisa, Claudio Favre, Piergiorgio Macchia (2
patients) Oncoematologia Pediatrica, Ospedale Pausilipon,
Napoli, Mimmo Ripaldi, Vincenzo Poggi (1 patient).
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